×
About 15,558 results

ALLMedicine™ Chronic Lymphocytic Leukemia Center

Research & Reviews  4,567 results

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Secondary Acquisition of t...
https://doi.org/10.1016/j.clml.2021.10.017
Clinical Lymphoma, Myeloma & Leukemia; Zhao Y, McCracken J et. al.

Nov 30th, 2021 - Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) occasionally undergoes Richter transformation, mostly to diffuse large B-cell lymphoma, but its evolution to other types of B-cell lymphoma is rare. We report a CLL evolved to mantl...

Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with...
https://doi.org/10.1182/bloodadvances.2021006215
Blood Advances; Bagacean C, Letestu R et. al.

Nov 30th, 2021 - Immunocompromised individuals such as chronic lymphocytic leukemia (CLL) patients are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate SARS-CoV-2-specific antibody responses in CLL patients, after the...

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
https://clinicaltrials.gov/ct2/show/NCT01087333

Nov 25th, 2021 - Background: Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which are being developed by the Laboratory of Molecular Biolo...

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04599634

Nov 25th, 2021 - Background: Indolent B-cell malignancies are associated with frequent disease relapse Standard frontline therapy includes a monoclonal anti-CD20 antibody with or without chemotherapy; novel targeted therapies have changed the treatment landscape a...

B-cell receptor isotypes differentially associate with cell signaling, kinetics, and ou...
https://doi.org/10.1172/JCI149308
The Journal of Clinical Investigation; Mazzarello AN, Gentner-Göbel E et. al.

Nov 24th, 2021 - In chronic lymphocytic leukemia (CLL), the B-cell receptor (BCR) plays a critical role in disease development and progression as indicated by the therapeutic efficacy of drugs blocking BCR signaling. However, the mechanism(s) underlining BCR respo...

see more →

Guidelines  8 results

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical ...
https://doi.org/10.6004/jnccn.2020.0006
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Feb 6th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940638
Leukemia Malcikova J, Tausch E et. al.

Feb 23rd, 2018 - In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. On these grounds...

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Vers...
https://doi.org/10.6004/jnccn.2017.0030
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Zelenetz AD et. al.

Mar 10th, 2017 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmu...

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841457
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Mar 5th, 2015 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the develop...

Non-Hodgkin's lymphomas, version 1.2013.
https://doi.org/10.6004/jnccn.2013.0037
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Wierda WG et. al.

Mar 15th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recomme...

see more →

Drugs  44 results see all →

Clinicaltrials.gov  324 results

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
https://clinicaltrials.gov/ct2/show/NCT01087333

Nov 25th, 2021 - Background: Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which are being developed by the Laboratory of Molecular Biolo...

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04599634

Nov 25th, 2021 - Background: Indolent B-cell malignancies are associated with frequent disease relapse Standard frontline therapy includes a monoclonal anti-CD20 antibody with or without chemotherapy; novel targeted therapies have changed the treatment landscape a...

A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece
https://clinicaltrials.gov/ct2/show/NCT04159779

Nov 23rd, 2021 - This study is being done to evaluate the clinical outcomes of Chronic Lymphocytic Leukemia (CLL) participants treated with venetoclax as routine standard of care in Greece. The decision to treat with venetoclax is made by the participant's physici...

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
https://clinicaltrials.gov/ct2/show/NCT03986034

Nov 22nd, 2021 - This study aims to study the clonal dynamics and kinetics of response during the ramp-up phase of venetoclax in chronic lymphocytic leukemia (CLL). Key Eligibility Criteria: Diagnosis of CLL/SLL (treatment naive or relapsed/refractory) Must have d...

CHIP/CCUS Natural History Protocol
https://clinicaltrials.gov/ct2/show/NCT04102423

Nov 22nd, 2021 - Clonal Hematopoiesis of Indeterminate Potential (CHIP) has been defined as the presence of a somatic pathogenic variant associated with hematological malignancy, with an allele fraction of at least 2%, without morphological evidence of bone marrow...

see more →

News  1,271 results

Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients
https://www.medpagetoday.com/hematologyoncology/hematology/95921

Nov 29th, 2021 - A novel triplet regimen led to improved outcomes and was well tolerated in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), a phase II trial found. After a median follow-up of 25.8 months, ...

mRNA COVID-19 Vaccines May Decrease Efficacy in Lymphoid Malignancies
https://www.onclive.com/view/mrna-covid-19-vaccines-may-decrease-efficacy-in-lymphoid-malignancies

Nov 19th, 2021 - Patients with lymphoid malignancies, especially those who have received recent anti-CD20 antibody therapy, have reduced humoral responses to the mRNA COVID-19 vaccines, and as such, should continue to take precautionary measures against COVID-19 i...

The Evolving Therapeutic Landscape for Marginal Zone Lymphoma: Expert Perspectives
https://www.onclive.com/view/the-evolving-therapeutic-landscape-for-marginal-zone-lymphoma-expert-perspectives

Nov 17th, 2021 - SAMEH GABALLA, MD, MSc Assistant Professor, University of South Florida Assistant Member, Department of Malignant Hematology H. Lee Moffitt Cancer Center & Research Institute Tampa, FL ARIELA NOY, MD Medical Oncologist, Hematologic Maligna...

BTK Inhibitors, PI3K Inhibitors, and CAR T-Cell Therapy Shake Up Hematologic Malignancies Armamentarium
https://www.onclive.com/view/btk-inhibitors-pi3k-inhibitors-and-car-t-cell-therapy-shake-up-hematologic-malignancies-armamentarium

Nov 15th, 2021 - BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies have changed the treatment landscape of many hematologic malignancies, said Harry Paul Erba, MD, PhD, who added that the evolving paradigms underscore the need for individualized decision m...

Dr. Stephens Discusses Optimizing Treatment Selection in CLL
https://www.onclive.com/view/dr-stephens-discusses-optimizing-treatment-selection-in-cll

Nov 9th, 2021 - Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses optimizing treatment selection in chronic lymphocytic leukemia (CLL). Numerous treatment options are available for use in patients with CLL,...

see more →

Patient Education  9 results see all →